All ASS1-loss patients were non-responders to their neoadjuvant therapy, and all patients also suffered from vital lymph node metastases as an expression of a very high risk of recurrence. This evidence concerns the gene ASS1 and metastatic malignant neoplasm in the lymph nodes.